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Tuberculosis: A Global Threat
Tuberculosis (TB) remains one of the
major causes of infectious morbidity and
mortality globally, claiming millions of
lives every year. Approximately one-third
of the world’s population is estimated to be
infected with Mycobacterium tuberculosis, giv-
ing rise to 9.4 million new cases of active
TB disease each year [1]. The majority of
the TB burden exists in 22 high-burden
countries, but with immigration and global
travel TB is difficult to eliminate from any
one country [1–4].
The Bacille Calmette-Gue ´rin (BCG)
vaccine, first introduced in 1921, contin-
ues to be the only vaccine used to prevent
TB [5,6]. Despite nearly a century of use,
BCG remains controversial, with known
variations in BCG substrains, vaccine
efficacy, policies, and practices across the
world. Global information on BCG poli-
cies and practices may be useful for clinical
interpretation of diagnostic tests as well as
in the design of novel TB vaccines that are
under development.
BCG: A Range of Global Policies
While most experts agree that BCG is
efficacious against severe forms of child-
hood TB, its efficacy against TB in adults
is highly variable [7]. As a result of the
uncertain efficacy of the BCG vaccine,
countries have developed very different
BCG vaccination policies. Some countries,
such as the United Kingdom, have or have
had universal BCG vaccination programs,
while others (including Canada and the
United States) either only recommended
BCG for high-risk groups or did not
advocate BCG countrywide. The Canadi-
an situation was further complicated by
differing policies across provinces, where
some provinces underwent mass vaccina-
tion programs and others did not. In
addition, BCG vaccination policies have
varied by the number of doses used, the
age at which vaccination was given, and
the methods used to deliver the vaccine
(although most countries today use only
the intradermal route) [8]. Vaccination
practices also have changed within and
across countries over the years, reflecting
changes in evidence, health policy, public
perception, increasing or decreasing TB
incidence, and HIV incidence. As a result
of these changes to the BCG policies in
various countries, it is necessary to not
only know the current BCG vaccination
policies but also past policies and applica-
ble changes when dealing with adults who
received BCG vaccination in childhood.
Since the publication of the M. tubercu-
losis genome, comparative genomic studies
have documented that BCG vaccine
strains have evolved and differ from each
other and from the original BCG first used
in 1921 [9]. Because these genetic differ-
ences affect antigenic proteins, these
changes may translate into differences in
efficacy and effect on the tuberculin skin
test (TST) [10,11]. Work done by Ritz and
Curtis looking at global BCG strain
variations demonstrates the diversity of
strains used by different countries and
even within the same countries [12]. They
found that 44% (83/188) of countries
reported using more than one BCG strain
type during an interval of only 5 years.
This highlights the importance of docu-
menting BCG vaccination practices for
both clinical and research purposes.
Clinicians cannot be expected to know
BCG practices in all countries, and
immigrants themselves may not know
about the vaccination policies in their
countries of birth (most adult immigrants
are unlikely to retain childhood vaccina-
tion records). Information on diversity of
BCG policies between countries and
across time may be helpful for better
interpretation of TB diagnostics as well as
design of new TB vaccines. To our
knowledge, there is no single, comprehen-
sive, searchable database of BCG policies
and practices (past and present) across the
world. We developed the ‘‘BCG World
Atlas: A Database of Global BCG Vacci-
nation Policies and Practices,’’ a database
containing BCG information from each
country across all world regions (http://
www.bcgatlas.org/). Figure 1 shows the
homepage of the Atlas. To make this
resource practical and useful for clinicians,
public health practitioners, and research-
ers alike, our database captures both
present and previous policy and practices
within a country, as well as any applicable
changes.
The Health in Action section is a forum for
individuals or organizations to highlight their
innovative approaches to a particular health
problem.
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Detailed information onpast andpresent
BCG vaccination policies and practices
were collected from as many countries as
possible by one of three methods. First,
short respondent-completed questionnaires
were sent out to at least two individuals in
each country. Questionnaires were sent to
experts in TB research, TB control pro-
grams, or public health/vaccination pro-
grams. Whenever possible, an attempt was
made to collect two completed question-
naires from each country in order to
validate the data. Questionnaires were
available in English, French, and Spanish,
and were designed to capture both current
policy and actual BCG practices, as well
any applicable changes that had occurred
over the last 25 years. Detailed questions
asked for information concerning past as
well as current practices, the timing and
nature of changes to the policies and or
practices, repeat, multiple, or booster shots,
information concerning tuberculin skin
testing in conjunction with BCG vaccina-
tion, influence of HIV on the decision to
vaccinate, and vaccine strain differences. A
total of 89 completed questionnaires were
received over a 2-year period. Second, data
were abstracted from published papers,
reports, and available government policy
documents retrieved through literature
searches on PubMed and via the World
Wide Web. Third, we used immunization
data available from the World Health
Organization Vaccine Preventable Diseas-
es Monitoring System (http://apps.who.
int/immunization_monitoring/en/global-
summary/ScheduleSelect.cfm), which pro-
vide basic information on all vaccines
currently in use in each country [13].
Based on the data generated by all
methods, countries were grouped into
three main categories: A), the country
currently recommends universal BCG
vaccination at a certain age; B), the
country used to recommend universal
BCG vaccination but currently does not;
or category C), BCG vaccination is
recommended only for selected high-risk
groups or was never recommended.
Summary of Findings
The beta version of the Atlas went live
in the fall of 2008 with completed
questionnaires on BCG vaccination from
62 countries. Since that time, more data
have been added and several improve-
ments have been made. As of October
2010, we have collected data concerning
BCG vaccination policies and practices for
180 of 209 (86%) countries worldwide that
we approached. The database is available
as an interactive Web site at http://www.
bcgatlas.org/, where information for a
particular country’s BCG policy, along
with its estimated World Health Organi-
zation (WHO) TB incidence statistics, can
be viewed alongside a graphical map.
Among the 180 countries with available
data, 157 countries currently recom-
mend universal BCG vaccination, while
the remaining 23 countries have either
stopped BCG vaccination (due to a
reduction in TB incidence), or never
recommended mass BCG immunization
and instead favored selective vaccination
of ‘‘at risk’’ groups (Figure 2). Complete
questionnaire data were available for 77
countries, while remaining data were
extracted from published sources.
Many countries began BCG vaccination
programs in the 1940s–1980s, though some
countries such as Romania and Uzbekistan
report vaccination campaigns as early as
1928 and 1937, respectively, while some
sub-Saharan African nations such as Ni-
geria and Sierra Leone only began BCG
Summary Points
N Despite nearly a century of use, the Bacille Calmette-Gue ´rin (BCG) vaccine
continues to be controversial, with known variations in BCG substrains and
vaccine efficacy.
N Because vaccination policies and practices vary across time and countries, we
created the first searchable, online, open access database of global BCG
vaccination policy and practices, the BCG World Atlas (http://www.bcgatlas.org/),
which contains detailed information on current and past BCG policies and
practices for over 180 countries.
N The Atlas is for clinicians, policymakers, and researchers and provides
information that may be helpful for better interpretation of tuberculosis (TB)
diagnostics as well as design of new TB vaccines.
Figure 1. Home page of the BCG World Atlas (http://www.bcgatlas.org/) and example of BCG policies and practices in Japan.
doi:10.1371/journal.pmed.1001012.g001
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countries have ceased universal BCG
vaccination programs; Spain and Denmark
were among the first, stopping in 1981 and
1986, respectively, while Austria and Ger-
many had stopped by 1990 and 1998. The
remaining countries, including the Isle of
Man, Slovenia, UK, Finland, and France,
all ceased their BCG vaccination cam-
paigns between 2005 and 2007. While
these countries may have ceased mass
universal vaccination programs, many do
continue to provide BCG vaccination
selectively to high-risk individuals, includ-
ing those involved in high TB risk occupa-
tions and/or travel,
and infants born into high TB risk
environments.
We identified 49 countries that report-
ed changes to their BCG vaccination
policy in the past 20 years. Twenty-seven
countries reported major changes to their
BCG policy within the last 10 years. Of
particular interest is the large number
(n=33) of countries that had multiple
vaccination programs in the past, but
have since ceased revaccination, and now
use a single BCG vaccination schedule
(Table 1). These revaccination policy
changes were as recent as 2007. Sixteen
countries continue to give an additional
BCG vaccination after the initial BCG,
known as a booster vaccination (Table 2),
while Kazakhstan, Belarus, Uzbekistan,
and Turkmenistan continue to recom-
mend three BCG vaccinations, with the
third given between the ages of 12 and
15. Multiple revaccinations may lead to a
delayed hypersensitivity reaction also
known as the Koch response (phenome-
non), where a person previously infected
with M. tuberculosis is reinfected intracu-
taneously, resulting in a local inflamma-
tory reaction marked by necrotic lesions
that develops rapidly and heals quickly
[14].
Changes in vaccine strain were the most
frequent type of change reported (n=42),
and many countries have employed sever-
al strains over the course of their BCG
vaccination program’s existence, with
countries reporting strain changes as
recently as 2008.
Additional variations in BCG vacci-
nation administration are seen across
countries. Currently, eight countries
recommend TST post–BCG vaccina-
tion, and two other countries had this
policy but have since ceased. Estimated
national BCG coverage ranged from
70% to 100%; however, frequently these
estimates were not available or were
several years out of date. Finally, 19
countries that did not recommend uni-
versal BCG vaccination did report BCG
vaccination for certain at-risk groups,
most frequently health care workers and
infants living in high-risk TB settings.
These variations highlight the impor-
Figure 2. Map displaying BCG vaccination policy by country. A: The country currently has universal BCG vaccination program. B: The country
used to recommend BCG vaccination for everyone, but currently does not. C: The country never had universal BCG vaccination programs.
doi:10.1371/journal.pmed.1001012.g002
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across regions both for clinical purposes
and research.
Open Access through an
Interactive Web Site
The Atlas is an interactive Web site that
allows users to select and view information
concerning a country’s past and current
BCG vaccination policy either by clicking
on an interactive map or by selecting the
country of interest from a drop-down list
(Figure 1). The Web site is available to the
public and is free of charge. Over the past
year (during its beta phase), we have
recorded over 6,000 visits to the site, with
a steady increase in traffic over time.
Implications for Diagnosis of TB
While novel diagnostics have been
developed for latent TB infection (LTBI)
[15–19], the TST continues to be the most
widely used diagnostic test worldwide [20].
False positives can occur in BCG-vacci-
nated individuals, complicating interpre-
tation of test results [21]. However,
Table 1. Countries that have ceased booster BCG vaccinations (n=33).
Country
Current BCG
Vaccination
Currently
Recommend a
Booster BCG
Booster BCG
given in past?
Timing of old
BCG boosters
Year Booster
BCG stopped
Argentina Yes No Yes 6 & 16 yrs 1995 & 2007
Bosnia and Herzegovina Yes No Yes 3, 5, 7, 13, & 19 yrs 1996
Brazil Yes No Yes 6 yrs 2006
Bulgaria Yes No Yes 7 months, 7, 11, & 17 yrs Unknown
Chile Yes No Yes 5 yrs 2004
China Yes No Yes Unknown Unknown
Estonia Yes No Yes 7 yrs 2003
Finland No No Yes School-age (if TST negative) 1990
France No No Yes Unknown Unknown
Hong Kong, China Yes No Yes Primary school 2000
Iran, Islamic Rep. Yes No Yes 4–6 yrs 1999
Ireland Yes No Yes 11–12 yrs 1996
Italy No No Yes 9 yrs 2001
Japan Yes No Yes 6–13 yrs
(every year if TST negative)
2003
Korea, Rep. Yes No Yes 8 yrs 2007
Latvia Yes No Yes 7, 12, & 15 yrs 1974: (12 yrs ceased), 1993:
(7 yrs ceased), 1998:
Ceased all revaccination
Macedonia, FYR Yes Yes: Age: 7 Yes 14 yrs Unknown
Mexico Yes No Yes 6 yrs (school age) 1998
Mongolia Yes No Yes 8, 15, & 18 yrs 1974–2006
Poland Yes No Yes 7 yrs 2005
Romania Yes No Yes 7, 14, & 18/21 yrs 1992–1993
Serbia and Montenegro Yes No Yes 2, 7, 10, & 14 yrs 1997
Singapore Yes No Yes 12 or 16 yrs 2001
Slovak Republic Yes No Yes 7 & 14 yrs 2001
Slovenia No No Yes 14–15 yrs 1947–1996
South Africa Yes No Yes Unknown Unknown
Sweden No No Yes 7 & 15 yrs
(if non-reactive to TST)
1965: stopped booster at 7 yrs,
1986: stopped booster at
15 yrs, 1979: stopped boosters
for military conscripts
Taiwan Yes No Yes 12 yrs 1982–1997
Thailand Yes No Yes Unknown Unknown
Turkey Yes No Yes 7, 14, & 20 yrs 1997: stopped boosters
at 14 & 20 yrs, 2006:
stopped boosters at 7 yrs
Uruguay Yes No Yes 6–12 yrs 1980–1993
Uzbekistan Yes Yes: Ages 7 & 14 Yes 12, 15, 20, 25, & 30 yrs 1997
Zambia Yes No Yes Unknown Unknown
doi:10.1371/journal.pmed.1001012.t001
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plays an important role [9,10]; in a meta-
analysis, Farhat et al. found BCG vacci-
nation at infancy has only a minimal effect
on TST specificity, particularly if the TST
is done more than 10 years after the BCG
was administered, whereas BCG later in
life or if given more than once led to more
frequent, larger, and pronounced TST
reactions [21]. The Atlas may help
clinicians interpret TST by providing the
information necessary to assess whether
the TST is a valid diagnostic tool in a
particular patient, or when alternative
diagnostics may be preferable.
Newly available interferon-gamma re-
lease assays (IGRAs) are more specific
than TST because they are not affected by
previous BCG vaccination [19,22]. Recent
meta-analyses show that the specificity of
IGRA is high in all populations, and will
be of greatest utility in BCG-vaccinated
populations [19,23]. For example, TST
may be less specific for LTBI in Japan
[24,25] (Figure 1) or other countries that
revaccinate with BCG or have recently
ceased revaccination programs (Table 1);
in these settings, IGRAs may be more
specific than the TST. Conversely, the
TST should not suffer from non-specificity
in India, for example, where BCG is given
once at birth, as has been borne out by
research studies [26–28]. One of the
applications of this database is its ability
to identify populations where repeated
BCG immunizations were administered
or where BCG was administered after
infancy, as these populations are most
likely to benefit from the use of highly
specific IGRAs for the diagnosis of LTBI
(Figure 3 and Box 1). Table 3 lists the 22
countries identified by the WHO as
representing 80% of the global TB
burden, and their respective BCG policies
[29]. The six bolded countries have either
recommended booster BCGs in the past or
currently doing so, while the remaining 16
countries have not recommended booster
BCG vaccinations.
Along with novel approved diagnostics
such as the IGRAs, there exist other novel
diagnostics in research and development
stages that use antigens that vary across
BCG strains. These include, for example,
the MPB64 patch test and serological tests
for the diagnosis of TB [30–32]. The BCG
policies and practices of a particular
country may influence the use and utility
of these tests in the future.
Implications for Immunization
Strategies
Recently there has been renewed inter-
est in developing novel vaccines for TB.
According to the Global Plan to Stop TB,
2006–2015, ‘‘effective TB vaccines will be
an essential component of any strategy to
eliminate tuberculosis (TB) by 2050’’ [33].
In 2009, at least six different vaccine
candidates completed Phase I clinical
trials, and three are currently in Phase II
[18]. Novel vaccine candidates include
both live and sub-unit vaccines. Many
employ a heterologous ‘‘prime-boost’’
strategy that complements the existing
immune response to BCG. Either the
existing BCG or a new recombinant
BCG is administered first, and then the
new vaccine serves as a ‘‘booster’’. Differ-
ent vaccines are being developed that
could be administered in infants and
young children pre-exposure, and others
as adjuvants to chemotherapy post-expo-
sure. Given that novel vaccines may work
to complement the existing BCG, it may
be relevant to know what previous BCG
vaccination individuals have had, how
many and at what ages prior to adminis-
tering novel ‘‘booster vaccines’’. Similarly,
we may be concerned that antigens from
the primary vaccination with BCG may
affect the booster vaccine. Therefore, in
countries where revaccination with BCG
was practiced, we might expect higher
rates of Koch response, or delayed hyper-
sensitivity response.
In 2007, the WHO revised its policy on
BCG vaccination of children with HIV,
making HIV infection in infants a full
contra-indication for BCG vaccination,
even in settings highly endemic for TB
[34]. In 2008, the IUATLD BCG Work-
ing Group published a consensus state-
ment supporting the revised WHO BCG
vaccination policy, but recommended that
current universal BCG immunization of
infants continue in countries highly en-
Table 2. Countries that currently recommend multiple BCG vaccinations (n=16).
Country Age of 1st BCG Age of 2nd BCG Age of 3rd BCG
Armenia At birth 7 yrs, if no scar -
Belarus After birth, within 1 yr 7 yrs 14 yrs
Croatia At birth 14 yrs -
Czech Republic At birth 11 yrs -
Fiji At birth 6 yrs -
Kazakhstan At birth 6 yrs 12 yrs
Macedonia, FYR At birth 7 yrs -
Moldova After birth, within 1 yr 6–7 yrs -
Nigeria At birth 5 yrs (but not yet incorporated into
the immunization schedule)
-
Norway At birth 13–15 yrs -
Philippines At birth Not specified -
Russian Federation At birth 7–14 yrs -
Tunisia At birth 6 yrs -
Turkmenistan After birth, within 1 yr 6–7 yrs 15 yrs
Ukraine After birth, within 1 yr 7 yrs -
Uzbekistan At birth 7 yrs 14 yrs
doi:10.1371/journal.pmed.1001012.t002
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grams in place for implementing selective
deferral of BCG vaccination in infants
exposed to HIV [35]. As countries re-
spond to these new global recommenda-
tions, changes in vaccination policies
because of the HIV epidemic should be
captured in future updates of the Atlas.
Conclusions
Despite nearly a century of use, the
BCG vaccine continues to be controver-
sial, and policies and practices vary widely
across the world. Many countries have
experienced major changes in regards to
revaccination over the past 20 years. The
BCG World Atlas: A Database of Global
BCG Vaccination Policy and Practices is
an interactive Web site that attempts to
provide the clinician, researcher, and
pubic health practitioner alike with re-
Figure 3. Countries most likely to benefit from highly specific IGRAs for the diagnosis of LTBI. One of the applications of this database is
its ability to identify populations where repeated BCG immunizations were administered or where BCG was administered after infancy, as these
populations are most likely to benefit from the use of highly specific IGRAs for the diagnosis of LTBI.
doi:10.1371/journal.pmed.1001012.g003
Box 1. Case Study Using the BCG Atlas.
N A 30-year-old man, born in the Slovak Republic
N Recently arrived in Canada, as a new immigrant
N TST-positive (10 mm), and unremarkable chest X-ray
N No known contact with an active TB case
N No documentation of BCG vaccination status, but has a vague memory of
receiving more than one BCG shot
From the BCG Atlas:
N Slovak Republic: Universal BCG vaccinations at birth and BCG boosters at ages 7
and 14 until 2001
R This individual probably received multiple BCG vaccinations post-infancy,
which may seriously compromise specificity of the TST; clinician decides to order
an IGRA, and based on a negative IGRA and other clinical factors, clinician decides
against recommending isoniazid preventative therapy (IPT).
PLoS Medicine | www.plosmedicine.org 6 March 2011 | Volume 8 | Issue 3 | e1001012sources and information necessary to
interpret current and novel TB diagnostics
and conduct fruitful research on novel
vaccines. Most critically, this is a useful
resource for the TB community and is
publicly available free of charge through
an easy-to-use Web site.
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